Shawn Hassler, MD
Infectious Disease · San Francisco, CANPI 1427122928
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $313,210 of the $433,180 with a category attached, or 72.3%. 36 manufacturers reported payments, led by Viiv Healthcare Company at 54.3% of the total. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,329 payments — averaging $325.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$235K
- Gilead$157K
- Napo Pharmaceuticals Inc$14K
- Theratechnologies Inc.$13K
- Merck$5K
- EMD Serono, Inc.$3K
- plus $7K from 30 others
Across 1,438 payments — averaging $2989.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.4M
- AbbVie$1.2M
- Modernatx, Inc.$840K
- Orexo US, Inc.$397K
- Viiv Healthcare Company$177K
- Pfizer$149K
- plus $209K from 11 others
What the payments were for
- Consulting fees$52,99512%
- Speaking & faculty fees$313,21072%
- Travel & lodging$36,6978%
- Food & beverage$29,9317%
- Education$3460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$433,180 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 459 | $1,995,059 |
| SerostimSomatropin | 60 | $1,157,103 |
| DovatoDolutegravir Sodium/Lamivudine | 175 | $608,989 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 132 | $492,044 |
| TivicayDolutegravir Sodium | 180 | $449,916 |
| DescovyEmtricitabine/Tenofov Alafenam | 149 | $392,822 |
| PifeltroDoravirine | 171 | $314,857 |
| Egrifta SvTesamorelin Acetate | 35 | $264,004 |
| JulucaDolutegravir/Rilpivirine | 57 | $223,552 |
| RukobiaFostemsavir Tromethamine | 24 | $217,753 |
| MytesiCrofelemer | 49 | $194,087 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 45 | $192,785 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 36 | $181,687 |
| PrezcobixDarunavir/Cobicistat | 78 | $180,161 |
| CabenuvaCabotegravir/Rilpivirine | 21 | $140,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $157,059 | $2,501,010636 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Rukobia, Triumeq | $235,220 | $1,833,912502 claims |
| EMD Serono, Inc.Serostim | $2,627 | $1,157,10360 claims |
| MerckPifeltro, Isentress, Januvia | $4,502 | $478,117269 claims |
| Theratechnologies Inc.Egrifta Sv | $13,460 | $264,00435 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $408 | $211,244110 claims |
| Napo Pharmaceuticals IncMytesi | $13,515 | $194,08749 claims |
| Janssen Products, LPSymtuza | $299 | $181,68736 claims |
| AbbVieVraylar, Creon, Ubrelvy | $1,094 | $160,24494 claims |
| Janssen Scientific Affairs, LLCEdurant | $95 | $100,07968 claims |
| Antares Pharma, Inc.Xyosted | $854 | $76,024119 claims |
| PfizerEliquis | $109 | $53,93651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in San Francisco
- Abhijit LimayeSan Francisco$152K
- Joel PalefskySan Francisco$68K
- Monica GandhiSan Francisco$60K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.